$130.93
+0.71 (+0.54%)
Last updated: Apr 22, 2026 14:34
Fundamentals Overview
Neurocrine Biosciences, Inc. is in the middle of its 52-week range with moderate valuation, trading relatively flat today.
Valuation moderate
Intrinsic value (DCF)
+316.8% upside vs price
Profitability
Risk (Beta)
0.35 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
DCF +316.8% upside vs price · Analyst grade: A-
Pressures (Sell):
Sentiment weakening (1 downgrade) · 3M vs S&P 500: -7.7%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: A-. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 14, Equal Weight: 2, Market Perform: 1, Neutral: 1, Outperform: 5, Overweight: 7.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $545.71; current price is $130.93. That’s a +316.8% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 28.04 |
| DCF value (model) | $545.71 (316.8% upside) |
| PEG (TTM) | 0.7 |
| P/B (TTM) | 4 |
| P/S (TTM) | 4.59 |
| P/FCF (TTM) | 17.55 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 3.39 |
| Quick Ratio (TTM) | 3.3 |
| Cash Ratio (TTM) | 0.96 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 16.73% |
| Gross margin (TTM) | 98.18% |
| Operating margin (TTM) | 21.64% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for NBIX.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2026-04-10 |
| Wedbush | maintain | Outperform | Outperform | 2026-04-07 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-04-07 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-04-07 |
| Citigroup | maintain | Buy | Buy | 2026-04-07 |
| Needham | maintain | Buy | Buy | 2026-04-06 |
| JP Morgan | maintain | Overweight | Overweight | 2026-03-12 |
| JP Morgan | maintain | Overweight | Overweight | 2026-02-17 |
| Truist Securities | maintain | Buy | Buy | 2026-02-17 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-02-13 |
| BMO Capital | maintain | Market Perform | Market Perform | 2026-02-12 |
| Wedbush | maintain | Outperform | Outperform | 2026-02-12 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-12 |
| Needham | maintain | Buy | Buy | 2026-02-12 |
| RBC Capital | maintain | Outperform | Outperform | 2026-02-12 |
| Citigroup | maintain | Buy | Buy | 2026-02-12 |
| UBS | maintain | Buy | Buy | 2026-01-23 |
| JP Morgan | maintain | Overweight | Overweight | 2026-01-12 |
| Truist Securities | maintain | Buy | Buy | 2026-01-08 |
| Morgan Stanley | downgrade | Overweight | Equal Weight | 2026-01-08 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-12-17 |
| Mizuho | maintain | Neutral | Neutral | 2025-12-12 |
| Stifel | maintain | Buy | Buy | 2025-12-11 |
| RBC Capital | maintain | Outperform | Outperform | 2025-12-08 |
| TD Cowen | maintain | Buy | Buy | 2025-12-05 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-11-11 |
| JP Morgan | maintain | Overweight | Overweight | 2025-11-03 |
| Truist Securities | maintain | Buy | Buy | 2025-10-30 |
| Piper Sandler | maintain | Overweight | Overweight | 2025-10-29 |
| RBC Capital | maintain | Outperform | Outperform | 2025-10-29 |